Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
The molecular interaction between viral RNA and the cytosolic sensor RIG-I represents the initial trigger in the development of an effective immune response against infection with RNA viruses, resulting in innate immune activation and subsequent induction of adaptive responses. In the present study, the adjuvant properties of a sequence-optimized 5'-triphosphate-containing RNA (5'pppRNA) RIG-I agonist (termed M8) were examined in combination with influenza virus-like particles (VLP) (M8-VLP) expressing H5N1 influenza virus hemagglutinin (HA) and neuraminidase (NA) as immunogens. In combination with VLP, M8 increased the antibody response to VLP immunization, provided VLP antigen sparing, and protected mice from a lethal challenge with H5N1 influenza virus. M8-VLP immunization also led to long-term protective responses against influenza virus infection in mice. M8 adjuvantation of VLP increased endpoint and antibody titers and inhibited influenza virus replication in lungs compared with approved or experimental adjuvants alum, AddaVax, and poly(I·C). Uniquely, immunization with M8-VLP stimulated a TH1-biased CD4 T cell response, as determined by increased TH1 cytokine levels in CD4 T cells and increased IgG2 levels in sera. Collectively, these data demonstrate that a sequence-optimized, RIG-I-specific agonist is a potent adjuvant that can be utilized to increase the efficacy of influenza VLP vaccination and dramatically improve humoral and cellular mediated protective responses against influenza virus challenge.


OBJECTIVE
The development of novel adjuvants to increase vaccine immunogenicity is an important goal that seeks to improve vaccine efficacy and ultimately prevent infections that endanger human health. This proof-of-principle study investigated the adjuvant properties of a sequence-optimized 5'pppRNA agonist (M8) with enhanced capacity to stimulate antiviral and inflammatory gene networks using influenza virus-like particles (VLP) expressing HA and NA as immunogens. Vaccination with VLP in combination with M8 increased anti-influenza virus antibody titers and protected animals from lethal influenza virus challenge, highlighting the potential clinical use of M8 as an adjuvant in vaccine development. Altogether, the results describe a novel immunostimulatory agonist targeted to the cytosolic RIG-I sensor as an attractive vaccine adjuvant candidate that can be used to increase vaccine efficacy, a pressing issue in children and the elderly population.
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Vladimir
V
Beljanski
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Cindy
C
Chiang
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Greg A
GA
Kirchenbaum
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
David
D
Olagnier
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Chalise E
CE
Bloom
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Terianne
T
Wong
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Elias K
EK
Haddad
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Lydie
L
Trautmann
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA.
Ted M
TM
Ross
Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA john.hiscott@istitutopasteur.it.
John
J
Hiscott
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000235:genetics; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000071457:DEAD Box Protein 58; D053487:DEAD-box RNA Helicases / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology; D005260:Female; D057809:HEK293 Cells; D006389:Hemagglutinins, Viral / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D007114:Immunization; D053124:Influenza A Virus, H5N1 Subtype / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009439:Neuraminidase / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D009843:Oligoribonucleotides / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000401:mortality / Q000517:prevention & control* / Q000821:virology; D061251:Primary Cell Culture; D011971:Receptors, Immunologic; D016019:Survival Analysis; D058408:Th1-Th2 Balance / Q000187:drug effects; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D009843:Oligoribonucleotides; D011971:Receptors, Immunologic; D058425:Vaccines, Virus-Like Particle; D009439:Neuraminidase; C452820:RIGI protein, human; D000071457:DEAD Box Protein 58; D053487:DEAD-box RNA Helicases